The interim recommendations made by the National Drug Scheduling Advisory Committee (NDSAC) on March 5, 2023 that:

• Loratadine and its salts and preparations in products labelled for use in children aged 2 to 11 years, in package sizes containing greater than 140 mg of loratadine, remain in Schedule III
• Loratadine and its salts and preparations in products labelled for use in children aged 2 to 11 years, in package sizes containing no more than 140 mg of loratadine, be granted Unscheduled status
• Loratadine and its salts and preparations, in products labelled for use in individuals 12 years of age and older, remain Unscheduled

were finalized effective April 25, 2023. Final approval of the interim recommendations was made by NAPRA’s Board of Directors. In this case, NAPRA did not receive any comments during the 30-day review period. The National Drug Schedules will be revised accordingly.